Methyl 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxylate (21874-61-3)
This product(s) resides on a APICMO contract.
The ability to produce, synthesize and manufacture large quantities of Methyl 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxylate (21874-61-3) with quality control system under CGMP manufacturing
Methyl 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxylate (21874-61-3) Description
Methyl 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxylate is an intermediate typically in the synthesis of Methyl 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxylate commercially named Favipiravir, which is a unique viral RNA Polymerase inhibitor for the treatment of Influenza (potentially treat the novel coronavirus pneumonia), acting on viral genetic copying to prevent its reproduction. A practical and step-economic route to Favipiravir. The complete synthesis of favipiravir from 2-aminopyrazine.
Favipiravir was approved for marketing in Japan in March 2014 and used for antiviral treatment of influenza A and B. In addition to the influenza virus, the drug also showed good antiviral activity to a variety of RNA viruses, such as Ebola virus, sand virus, Bunia virus.
This product(s) resides on a APICMO contract. If you are viewing this page as a non-registered user, the price(s) displayed is List Price. To view your pricing, log in using your account number, or become a registered user by contacting one of our Customer Service teams. To place an order, contact APICMO Customer Service.
Methyl 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxylate (21874-61-3) Specifications
|Chemical Name or Material||methyl 3-hydroxy-6-bromopyrazine-2-carboxylate; HHFMFCVOODVACN-UHFFFAOYSA-N; |
FT-0749179; methyl 6-bromo-3-hydroxy-2-pyrazinecarboxylate
|Packaging||Aluminum Foil Bag|
|Molecular Weight (g/mol)||173.999|
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Bulk Ordering & Pricing:
Need larger quantities for your development, manufacturing or research applications?